{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:38:50Z","timestamp":1791398330858,"version":"4.3.3"},"reference-count":73,"publisher":"European Respiratory Society (ERS)","issue":"177","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2025,6,5]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>Several interstitial lung diseases (ILDs) with different aetiologies and pathogenic mechanisms may exhibit a progressive behaviour, similar to idiopathic pulmonary fibrosis, with comparable functional decline and early mortality. Progressive pulmonary fibrosis (PPF) is not a diagnosis but rather reflects a clinical phenotype. Identifying progression is challenging as variability exists, both between different ILDs as well as in the context of the same entity. The American Thoracic Society\/European Respiratory Society guidelines provide a useful framework for recognising the progressive behaviour of individual ILDs. Nevertheless, sometimes the \u201cone-size-fits-all\u201d approach to PPF may not lead to the best management decisions for individual patients. Real-life clinical practice presents multiple hurdles for practising clinicians and it is of utmost importance to target early those individuals that will benefit from antifibrotic treatment. This review aims to highlight several clinical points and suggest that, in certain cases, the strict rule of initiating antifibrotic treatment only upon disease progression may warrant some flexibility, particularly in the context of everyday clinical practice. Emphasis is placed on critically examining the criteria used to define progression across different ILDs, commenting on clinical issues such as disease severity at baseline, prevention of acute exacerbations, the definition of \u201cstandard treatment\u201d, the need for early access to appropriate treatment, prediction of progression, personalised medicine and an aetiologic approach. Engaging technology and artificial intelligence will play a role in the future. Until then, the best possible management decisions will rely on the judgment of treating clinicians, guided by existing evidence and patient needs.<\/jats:p>","DOI":"10.1183\/16000617.0023-2025","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T08:45:41Z","timestamp":1754469941000},"page":"250023","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Initiation of antifibrotic treatment in fibrosing interstitial lung disease: is the clock ticking till proven progression?"],"prefix":"10.1183","volume":"34","author":[{"given":"Athena","family":"Gogali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0774-3942","authenticated-orcid":false,"given":"Konstantinos","family":"Kostikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argyris","family":"Tzouvelekis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"2025090301551191000_34.177.250023.1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201308-1483ST"},{"key":"2025090301551191000_34.177.250023.2","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0100-2018"},{"key":"2025090301551191000_34.177.250023.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04507-2020"},{"key":"2025090301551191000_34.177.250023.4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00692-2018"},{"key":"2025090301551191000_34.177.250023.5","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1080\/03007995.2019.1647040","article-title":"Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management","volume":"35","author":"Wijsenbeek","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"2025090301551191000_34.177.250023.6","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","article-title":"Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025090301551191000_34.177.250023.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2005230"},{"key":"2025090301551191000_34.177.250023.8","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/art.42075","article-title":"Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: subgroup analysis of the INBUILD trial","volume":"74","author":"Matteson","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025090301551191000_34.177.250023.9","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30036-9"},{"key":"2025090301551191000_34.177.250023.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681"},{"key":"2025090301551191000_34.177.250023.11","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1136\/annrheumdis-2022-eular.749","article-title":"AB0658 nocebo effect on diarrhoea reported in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)","volume":"81","author":"Distler","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025090301551191000_34.177.250023.12","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30554-3"},{"key":"2025090301551191000_34.177.250023.13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2018-000289"},{"key":"2025090301551191000_34.177.250023.14","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151322"},{"key":"2025090301551191000_34.177.250023.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076"},{"key":"2025090301551191000_34.177.250023.16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2025090301551191000_34.177.250023.17","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1056\/NEJMoa2414108","article-title":"Nerandomilast in patients with idiopathic pulmonary fibrosis","volume":"392","author":"Richeldi","year":"2025","journal-title":"N Engl J Med"},{"key":"2025090301551191000_34.177.250023.18","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","article-title":"Nerandomilast in patients with progressive pulmonary fibrosis","volume":"392","author":"Maher","year":"2025","journal-title":"N Engl J Med"},{"key":"2025090301551191000_34.177.250023.19","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0076-2018"},{"key":"2025090301551191000_34.177.250023.20","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30341-8"},{"key":"2025090301551191000_34.177.250023.21","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399ST"},{"key":"2025090301551191000_34.177.250023.22","doi-asserted-by":"crossref","first-page":"790204","DOI":"10.3389\/fphar.2021.790204","article-title":"Outcomes and incidence of PF-ILD according to different definitions in a real-world setting","volume":"12","author":"Torrisi","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025090301551191000_34.177.250023.23","doi-asserted-by":"publisher","DOI":"10.1164\/RCCM.202205-0910LE"},{"key":"2025090301551191000_34.177.250023.24","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202201-0124OC"},{"key":"2025090301551191000_34.177.250023.25","doi-asserted-by":"crossref","first-page":"107242","DOI":"10.1016\/j.rmed.2023.107242","article-title":"Comparison of the diagnostic criteria for progressive pulmonary fibrosis in connective tissue disease related interstitial lung disease","volume":"212","author":"Lee","year":"2023","journal-title":"Respir Med"},{"key":"2025090301551191000_34.177.250023.26","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03187-2021"},{"key":"2025090301551191000_34.177.250023.27","doi-asserted-by":"crossref","first-page":"17534666231212301","DOI":"10.1177\/17534666231212301","article-title":"Factors for progressive pulmonary fibrosis in connective tissue disease-related interstitial lung disease","volume":"17","author":"Kim","year":"2023","journal-title":"Ther Adv Respir Dis"},{"key":"2025090301551191000_34.177.250023.28","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/acr.25347","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090301551191000_34.177.250023.29","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01396-2021"},{"key":"2025090301551191000_34.177.250023.30","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1513\/AnnalsATS.201806-362OC","article-title":"Does systemic sclerosis-associated interstitial lung disease burn out? Specific phenotypes of disease progression","volume":"15","author":"Guler","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"2025090301551191000_34.177.250023.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217455"},{"key":"2025090301551191000_34.177.250023.32","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1164\/rccm.202206-1143LE","article-title":"Progressive pulmonary fibrosis: should the timelines be taken out of the definition?","volume":"206","author":"Cottin","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2025090301551191000_34.177.250023.33","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02571-2021"},{"key":"2025090301551191000_34.177.250023.34","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.21037\/jtd-23-481","article-title":"Compare three diagnostic criteria of progressive pulmonary fibrosis","volume":"16","author":"Chen","year":"2024","journal-title":"J Thorac Dis"},{"key":"2025090301551191000_34.177.250023.35","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200210-1245OC"},{"key":"2025090301551191000_34.177.250023.36","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210035"},{"key":"2025090301551191000_34.177.250023.37","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00357-2015"},{"key":"2025090301551191000_34.177.250023.38","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ebiom.2019.10.050","article-title":"Endotype-phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease","volume":"50","author":"Hoffmann-Vold","year":"2019","journal-title":"EBioMedicine"},{"key":"2025090301551191000_34.177.250023.39","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200706-877OC"},{"key":"2025090301551191000_34.177.250023.40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12890-019-1030-4","article-title":"Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis","volume":"20","author":"Richeldi","year":"2020","journal-title":"BMC Pulm Med"},{"key":"2025090301551191000_34.177.250023.41","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-018-0907-8"},{"key":"2025090301551191000_34.177.250023.42","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1186\/s12931-022-02277-2","article-title":"Association between weight loss and mortality in idiopathic pulmonary fibrosis","volume":"23","author":"Kalininskiy","year":"2022","journal-title":"Respir Res"},{"key":"2025090301551191000_34.177.250023.43","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0071-2018"},{"key":"2025090301551191000_34.177.250023.44","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01339-2016"},{"key":"2025090301551191000_34.177.250023.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.06.049"},{"key":"2025090301551191000_34.177.250023.46","doi-asserted-by":"crossref","first-page":"00403-2024","DOI":"10.1183\/23120541.00403-2024","article-title":"Acute exacerbations in patients with progressive pulmonary fibrosis","volume":"10","author":"Kreuter","year":"2024","journal-title":"ERJ Open Res"},{"key":"2025090301551191000_34.177.250023.47","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12890-023-02532-2","article-title":"Incidence, risk factors, and prognosis of acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis","volume":"23","author":"Xie","year":"2023","journal-title":"BMC Pulm Med"},{"key":"2025090301551191000_34.177.250023.48","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0866"},{"key":"2025090301551191000_34.177.250023.49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113354"},{"key":"2025090301551191000_34.177.250023.50","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201809-1646OC"},{"key":"2025090301551191000_34.177.250023.51","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/jcm8010014","article-title":"Effects of corticosteroid treatment and antigen avoidance in a large hypersensitivity pneumonitis cohort: a single-centre cohort study","volume":"8","author":"De Sadeleer","year":"2018","journal-title":"J Clin Med"},{"key":"2025090301551191000_34.177.250023.52","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01983-2019"},{"key":"2025090301551191000_34.177.250023.53","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02026-2019"},{"key":"2025090301551191000_34.177.250023.54","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213201"},{"key":"2025090301551191000_34.177.250023.55","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201807-443OC"},{"key":"2025090301551191000_34.177.250023.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.08.1076"},{"key":"2025090301551191000_34.177.250023.57","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00092309"},{"key":"2025090301551191000_34.177.250023.58","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30433-2"},{"key":"2025090301551191000_34.177.250023.59","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00869-2018"},{"key":"2025090301551191000_34.177.250023.60","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00260-0"},{"key":"2025090301551191000_34.177.250023.61","first-page":"1182","article-title":"American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"2024","author":"Johnson","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2025090301551191000_34.177.250023.62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805435"},{"key":"2025090301551191000_34.177.250023.63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810699"},{"key":"2025090301551191000_34.177.250023.64","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00441-2023"},{"key":"2025090301551191000_34.177.250023.65","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.chest.2021.01.026","article-title":"Family history of pulmonary fibrosis predicts worse survival in patients with interstitial lung disease","volume":"159","author":"Cutting","year":"2021","journal-title":"Chest"},{"key":"2025090301551191000_34.177.250023.66","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01826-2"},{"key":"2025090301551191000_34.177.250023.67","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202112-2684OC"},{"key":"2025090301551191000_34.177.250023.68","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1164\/rccm.202206-1036ED","article-title":"Deep learning-based classification of fibrotic lung disease: can computer vision see the future?","volume":"206","author":"Choi","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2025090301551191000_34.177.250023.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.03.037"},{"key":"2025090301551191000_34.177.250023.70","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(21)00503-8","article-title":"Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis","volume":"10","author":"Bowman","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2025090301551191000_34.177.250023.71","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00308-2016"},{"key":"2025090301551191000_34.177.250023.72","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01641-2018"},{"key":"2025090301551191000_34.177.250023.73","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2024.06.006"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0023-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T08:55:30Z","timestamp":1756889730000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0023-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":73,"journal-issue":{"issue":"177","published-online":{"date-parts":[[2025,8,6]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1183\/16000617.0023-2025"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0023-2025","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}